StageZero Life Sciences Ltd. (SZLS.TO) Research

StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.

Market snapshot

Symbol
SZLS.TO
Price
$0.04
Day change
0.00%
Market cap
$630.0K
P/E ratio
-0.04x
52-week range
0.04-0.055
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • The BC Bud Corporation (BCBC.CN)
  • Bhang Inc. (BHNG.CN)
  • Heritage Cannabis Holdings Corp. (CANN.CN)
  • Clearmind Medicine Inc. (CMND.CN)
  • Empower Clinics Inc. (EPW.CN)
  • 4Front Ventures Corp. (FFNT.CN)
  • ScreenPro Security Inc. (SCRN.CN)
  • Sunniva Inc. (SNN.CN)

Open StageZero Life Sciences Ltd. (SZLS.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.